Core Heavyweights
PX13-R is a triple receptor agonist acting at the GIP, GLP-1 and glucagon receptors. Every PX1 Research lot is synthesized in a US cGMP-compliant facility, assayed by HPLC and LC-MS, and published with a lot-matched certificate of analysis.
Each PX13-R lot is released only after an independent purity panel. Certificates are published per lot and per strength so the batch number on your vial matches the report you can download.
PX13-R ships lyophilized. Reconstitute with bacteriostatic water containing 0.9% benzyl alcohol. Common working ratios below assume a standard U-100 insulin syringe.
Pricing steps down at 3, 5 and 10 vials on the product page, with subscription pricing available on 1, 2 and 3 month intervals.
Convert vial strength and bacteriostatic water volume into exact insulin-syringe unit marks.
Peptide reconstitution calculator
Concentration
5 mg/mL
Draw volume
0.05 mL
Insulin syringe
5 units (IU)
U-100 insulin syringe (100 units = 1 mL)
10 mg + 2 mL = 5 mg/mL. A 250 mcg dose = 5 units on a U-100 syringe (40 doses per vial).
For laboratory and research use only. Not for human or veterinary use.
Need solvent? Buy bacteriostatic water (10mL / 30mL)
PX1 Research supplies PX13-R in multiple lyophilized strengths, most commonly 10mg and 20mg vials, with higher-strength options for extended research programs.
2mL of bacteriostatic water in a 10mg vial yields 5mg per mL, so 10 units on a U-100 insulin syringe equals 500mcg.
Yes. Every lot has a published, lot-matched COA showing HPLC purity and LC-MS identity confirmation.